Bamaryl 4mg Glimepiride is an oral diabetes medicine

Bamaryl 4mg

Bamaryl 4mg

Glimepiride is an oral diabetes medicine that is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

Glimepiride, used to treat diabetes mellitus type 2. It is use is recommended together with diet and exercise It is taken by mouth.Glimepiride takes up to three hours for maximum effect and lasts for about a day.

It works mainly by increasing the amount of insulin released from the pancreas.It is classified as a second-generation sulfonylurea.

Glimepiride was patented in 1979 and approved for medical use in 1995. It is available as a generic medication. In 2017, it was the 64th most commonly prescribed medication in the United States, with more than twelve million prescriptions.

Mechanism of action

Like all sulfonylureas, glimepiride acts as an insulin secretagogue It lowers blood sugar by stimulating the

Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.

Pharmacokinetics

Gastrointestinal absorption is complete, with no interference from meals. Significant absorption can occur within one hour, and distribution is throughout the body, 99.5% bound to plasma protein. Metabolism is by oxidative biotransformation, it is hepatic and complete. First, the medication is metabolized to M1 metabolite by CYP2C9. M1 possesses about ​1⁄3 of pharmacological activity of glimepiride, yet it is unknown if this results in clinically meaningful effect on blood glucose. M1 is further metabolized to M2 metabolite by cytosolic enzymes. M2 is pharmacologically inactive. Excretion in the urine is about 65%, and the remainder is excreted in the feces.